Capoten

(Captopril)

ApprovedSmall molecule

Captopril is used to treat high blood pressure and heart failure by helping blood vessels relax and improving blood flow, which reduces the workload on the heart.[2] Capoten is currently approved and in use across 24 indications[4].[1]

Capoten is one of 646 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

645

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Metabolic SyndromeActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Mitral RegurgitationActive, not recruiting

Essential HypertensionApproved

Rheumatic DiseaseActive, not recruiting

Diabetic NephropathyActive, not recruiting

Type 2 Diabetes MellitusApproved

Primary AldosteronismActive, not recruiting

Severe Acute Respiratory SyndromeActive, not recruiting

FibrosisActive, not recruiting

Metabolic SyndromeApproved

Active, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

Essential HypertensionApproved

Approved

Rheumatic DiseaseApproved

Active, not recruiting

Diabetic NephropathyPhase 2

Active, not recruiting

Type 2 Diabetes MellitusApproved

Approved

Primary AldosteronismPreclinical

Active, not recruiting

Severe Acute Respiratory SyndromePhase 2

Active, not recruiting

FibrosisPhase 1/Phase 2

Active, not recruiting

Showing 10 of 24 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Capoten

SStandard Chem. & Pharm. Co., Ltd.

Approved

27 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Singulair

AstraZeneca

Preclinical

1 7

Stivarga

Bayer

Preclinical

1 8

Aimovig

Amgen

Preclinical

1 9

Aldactone

Pfizer

Preclinical

1 10

Nexavar

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension2 trials

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

Terminated·VVanderbilt University·Phase 1·NCT01292694·12 enrolled

Treatment of Supine Hypertension in Autonomic Failure

Completed·VVanderbilt University·Phase 1·NCT00223717·152 enrolled

Heart Failure2 trials

Study of Drug Therapy for Pediatric Heart Failure

Unknown status·CChina National Center for Cardiovascular Diseases··NCT06039540·200 enrolled

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

Type 1 Diabetic1 trial

Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs

Completed·TTanta University·N/A·NCT03660293·150 enrolled

Type 2 Diabetes1 trial

Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy

Unknown status·HHospital de Clinicas de Porto Alegre··NCT00935805·124 enrolled

Diabetic Nephropathy1 trial

Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy

Completed·SShiraz University of Medical Sciences·Phase 2/3·NCT00663949·70 enrolled

20 more indications

Fasting Conditions1 trial

Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions

Withdrawn· GSK logo

GSK·Phase 1·NCT04878315

Function1 trial

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

Unknown status·—·Phase 1/2·NCT01626469·24 enrolled

Type 2 Diabetes Mellitus1 trial

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Completed· Novartis logo

Novartis·Phase 4·NCT00660309·45 enrolled

Metastatic Cancer1 trial

In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer

Completed·NNorthwestern University·Phase 1/2·NCT00086723

Stem Cell Transplantation1 trial

Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation

Completed·NNorthwestern University·Phase 3·NCT00004230·35 enrolled

Vasoconstriction1 trial

Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Recruiting·UUniversity of Calgary··NCT05442463·200 enrolled

Tics1 trial

A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril

Completed·SSeoul National University Hospital·Phase 1·NCT06292091·12 enrolled

Unknown status·—·Phase 4·NCT04288700·100 enrolled

Metabolic Syndrome1 trial

Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression

Unknown status·—·Phase 4·NCT04485845·39 enrolled

Angiotensin Converting Enzyme1 trial

Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition

Completed·IInstituto de Cardiologia do Rio Grande do Sul·Phase 4·NCT01545479·5 enrolled

Duchenne1 trial

Effect of Captopril on GLS in Duchenne Myodystrophy

Recruiting·—·Phase 1·NCT06485661·20 enrolled

Severe Acute Respiratory Syndrome1 trial

Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04355429·230 enrolled

Radiation Injury1 trial

The Role and Intervention of TGF-β in Abdominal Radiation Injury

Unknown status·WWuhan University·Phase 2·NCT03613506·226 enrolled

Non-Small Cell Lung Cancer1 trial

Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

Terminated· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00077064·81 enrolled

Glioblastoma1 trial

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed·UUniversity of Ulm·Phase 1/2·NCT02770378·10 enrolled

High Blood Pressure1 trial

Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure

Completed·IInstituto Materno Infantil Prof. Fernando Figueira·Phase 4·NCT01761916·90 enrolled

Prolonged1 trial

Rapid Versus Prolonged Inpatient Up-Titration of Captopril

Unknown status·TThe Hospital for Sick Children·Phase 2·NCT00742040·50 enrolled

Fibrosis1 trial

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

Withdrawn·—·Phase 1/2·NCT04629651

Regulatory

FDA Approval Timeline[5]

Jan 17, 1985

CAPOTEN

NDA NDA018343

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Captopril. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Capoten drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Captopril compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Captopril. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA018343). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Standard Chem. & Pharm. Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Angiotensin-Converting Enzyme Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: SStandard Chem. & Pharm. Co., Ltd.

Capoten

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Hypertension2 trials

Heart Failure2 trials

Type 1 Diabetic1 trial

Type 2 Diabetes1 trial

Diabetic Nephropathy1 trial

Fasting Conditions1 trial

Function1 trial

Type 2 Diabetes Mellitus1 trial

Metastatic Cancer1 trial

Stem Cell Transplantation1 trial

Vasoconstriction1 trial

Tics1 trial

Ventricular Function1 trial

Mitral regurgitation1 trial

Capillary Hemangioma1 trial

Metabolic Syndrome1 trial

Angiotensin Converting Enzyme1 trial

Duchenne1 trial

Severe Acute Respiratory Syndrome1 trial

Radiation Injury1 trial

Non-Small Cell Lung Cancer1 trial

Glioblastoma1 trial

High Blood Pressure1 trial

Prolonged1 trial

Fibrosis1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News